WinstonWınston
Enovis Corporation logo

Enovis Corporation

ENOV
22
Medical - Devices · Healthcare
Winston Score
22
Winston is worried
Weak fundamentals across most pillars.

Enovis Corporation makes medical devices used to help people recover from injuries and surgeries. Its main products include braces, joint reconstruction implants, and physical therapy equipment sold to hospitals, orthopedic surgeons, and rehabilitation clinics. The company focuses on the orthopedics and reconstructive care market, and it expanded significantly after acquiring Colfax's medical segment and later buying Lima Corporate, a European joint implant maker.

Enovis earns money by selling its devices and implants directly to healthcare providers, primarily through a direct sales force. It operates across North America, Europe, and other international markets, generating roughly $2 billion in annual revenue. The company's competitive position relies on its broad product portfolio and surgeon relationships, but its thin operating margin and low return on invested capital suggest it is still working to absorb recent acquisitions efficiently. The key challenge ahead is improving profitability while integrating those acquisitions in a market with strong competition from larger rivals like Zimmer Biomet and Stryker.

Winston Score History

Politician Trades

3 trades / 12mo

1 Congressional buy and 2 sells on ENOV in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+5.4% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+84.8% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

1.7%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~3 months

$33M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Cash watch

Enovis Corporation has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
54.9%
Healthy — 54.9% gross margin
Operating Margin
3.4%
Thin — 3.4% operating margin
ROCE
0.7%
Weak — 0.7% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+6.0%
Slow sales growth (6.0% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
1.6%
Thin free cash flow (1.6%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.91
Moderate — manageable debt (0.91)
Interest Cover
1.08x
Dangerous — barely covers interest (1.1x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
no trend
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial